Published in Arthritis Res Ther on January 17, 2011
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Risk of major osteoporotic fracture after cardiovascular disease: a population-based cohort study in Taiwan. J Epidemiol (2012) 0.91
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther (2015) 0.88
Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int (2012) 0.87
Comparison of calibrated and uncalibrated bone mineral density by CT to DEXA in menopausal women. Climacteric (2011) 0.85
Investigation of the prevalent fall-related risk factors of fractures in elderly referred to Tehran hospitals. Med J Islam Repub Iran (2013) 0.81
Bone mineral density, adiposity, and cognitive functions. Front Aging Neurosci (2015) 0.81
Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality. Rheumatology (Oxford) (2015) 0.80
Osteoporosis Is Associated With High Risk for Coronary Heart Disease: A Population-Based Cohort Study. Medicine (Baltimore) (2015) 0.79
Peripheral arterial disease increases the risk of subsequent hip fracture in older men: the Health in Men Study. Osteoporos Int (2012) 0.79
Poststroke hip fracture: prevalence, clinical characteristics, mineral-bone metabolism, outcomes, and gaps in prevention. Stroke Res Treat (2013) 0.77
Vertebral fractures on routine chest computed tomography: relation with arterial calcifications and future cardiovascular events. Int J Cardiovasc Imaging (2014) 0.76
Neuropathy and the vascular-bone axis in diabetes: lessons from Charcot osteoarthropathy. Osteoporos Int (2013) 0.76
Bone Mineral Density Is Positively Related to Carotid Intima-Media Thickness: Findings From a Population-Based Study in Adolescents and Premenopausal Women. J Bone Miner Res (2016) 0.75
Cardiovascular risk factor analysis in patients with a recent clinical fracture at the fracture liaison service. Biomed Res Int (2014) 0.75
Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study. Arthritis Res Ther (2015) 0.75
Whole body bone tissue and cardiovascular risk in rheumatoid arthritis. J Osteoporos (2014) 0.75
Decreased Bone Mineral Density Is an Independent Predictor for the Development of Atherosclerosis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
The link between bone disease and cardiovascular complications in hemodialysis patients. Electron Physician (2016) 0.75
Arterial stiffness is not associated with bone parameters in an elderly hyperhomocysteinemic population. J Bone Miner Metab (2015) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Osteoclast differentiation and activation. Nature (2003) 18.59
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation (2007) 11.95
Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol (2010) 9.44
25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med (2008) 8.03
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA (1986) 7.23
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature (1997) 7.10
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med (1999) 6.92
Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev (2001) 6.77
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation (2000) 5.53
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med (1995) 5.27
Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest (1993) 4.54
LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science (2007) 4.27
Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A (2002) 4.22
Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol (2004) 4.02
Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab (2004) 3.75
Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab (2004) 3.59
Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res (2006) 3.57
Changes in proinflammatory cytokine activity after menopause. Endocr Rev (2002) 3.24
Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 3.06
Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab (2008) 3.00
Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation (1999) 2.95
Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2001) 2.93
Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med (2001) 2.79
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol (2004) 2.73
Cardiovascular diseases and risk of hip fracture. JAMA (2009) 2.69
Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res (2006) 2.58
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest (1994) 2.43
Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int (2001) 2.34
The association between low bone mass at the menopause and cardiovascular mortality. Am J Med (1999) 2.30
Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med (1994) 2.28
Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol (2007) 2.22
The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J (2001) 2.21
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest (1994) 2.13
Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem (2001) 2.02
In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun (2000) 1.97
Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res (1996) 1.96
Age at menopause as a risk factor for cardiovascular mortality. Lancet (1996) 1.94
1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation (1998) 1.94
Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord (2006) 1.94
Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke (2009) 1.88
Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol (2000) 1.87
Hyperkyphotic posture predicts mortality in older community-dwelling men and women: a prospective study. J Am Geriatr Soc (2004) 1.86
Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem (2000) 1.83
Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev (2004) 1.83
Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women. Stroke (2001) 1.78
Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet (1991) 1.78
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol (2001) 1.77
Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag (2009) 1.76
Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res (2002) 1.69
Association between systemic calcified atherosclerosis and bone density. Calcif Tissue Int (2007) 1.67
The mechanisms of estrogen regulation of bone resorption. J Clin Invest (2000) 1.66
Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis (2003) 1.64
Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int (2003) 1.63
Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol (2005) 1.62
Nitric oxide and bone. Immunology (2001) 1.60
Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vasc Biol (2003) 1.56
Volumetric BMD and vascular calcification in middle-aged women: the Study of Women's Health Across the Nation. J Bone Miner Res (2006) 1.54
Bone mineral density and stroke. Stroke (2003) 1.52
Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. Int J Cardiol (2005) 1.51
Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med (2006) 1.49
Atherosclerotic calcification: relation to developmental osteogenesis. Am J Cardiol (1995) 1.48
Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res (2002) 1.48
Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab (2003) 1.46
Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am J Epidemiol (2008) 1.45
Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol (2008) 1.45
Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. Bone (2003) 1.44
Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. Osteoporos Int (2006) 1.42
Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem (2000) 1.39
The association of bone mineral density with vitamin D receptor gene polymorphisms. Osteoporos Int (1999) 1.38
Cardiovascular diseases and future risk of hip fracture in women. Osteoporos Int (2007) 1.38
Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int (2003) 1.37
Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann N Y Acad Sci (2007) 1.37
Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Mol Cell Biochem (2006) 1.34
Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun (1998) 1.33
Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int (1998) 1.33
Bone mineral density is a predictor of survival. Calcif Tissue Int (1998) 1.32
Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int (2008) 1.31
Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int (2003) 1.29
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res (2002) 1.26
High-density lipoprotein regulates calcification of vascular cells. Circ Res (2002) 1.22
Coronary calcification and osteoporosis in men and postmenopausal women are independent processes associated with aging. Calcif Tissue Int (2006) 1.20
Menopausal and aging changes in muscle mass and bone mineral content. A roentgenographic study. J Bone Joint Surg Am (1966) 1.20
Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem Biophys Res Commun (2004) 1.20
The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int (2007) 1.19
Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev (2005) 1.19
Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol (2001) 1.15
Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men. Circulation (2009) 1.14
Lipid profile and bone paradox: higher serum lipids are associated with higher bone mineral density in postmenopausal women. J Womens Health (Larchmt) (2006) 1.14
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med (2006) 3.80
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 2.73
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis (2007) 2.67
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum (2009) 2.55
Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum (2005) 2.01
Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum (2006) 1.79
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum (2009) 1.77
Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm (2010) 1.75
Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis (2011) 1.62
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial. Ann Intern Med (2016) 1.51
Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum (2012) 1.48
Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int (2009) 1.47
Avoidance of activities in early symptomatic knee osteoarthritis: results from the CHECK cohort. Ann Behav Med (2012) 1.46
Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol (2012) 1.42
Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum (2012) 1.30
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis (2009) 1.29
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther (2012) 1.29
Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum (2003) 1.28
Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol (2005) 1.22
Osteoimmunology and osteoporosis. Arthritis Res Ther (2011) 1.20
Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum (2013) 1.12
Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis (2010) 1.10
Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin (2008) 1.10
Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum (2004) 1.10
Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep (2011) 1.06
Association of lower muscle strength with self-reported knee instability in osteoarthritis of the knee: results from the Amsterdam Osteoarthritis cohort. Arthritis Care Res (Hoboken) (2012) 1.03
Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep (2010) 1.01
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Arthritis Res Ther (2014) 1.00
Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol (2007) 1.00
Self-reported knee instability and activity limitations in patients with knee osteoarthritis: results of the Amsterdam osteoarthritis cohort. Clin Rheumatol (2012) 0.99
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol (2013) 0.98
Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective. Nat Clin Pract Rheumatol (2008) 0.97
Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum (2004) 0.97
Body mass index measurements have limited value for the assessment of body composition in rheumatoid arthritis: comment on the article by Wolfe and Michaud. Arthritis Care Res (Hoboken) (2013) 0.97
Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken) (2011) 0.97
HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis (2012) 0.95
A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) (2013) 0.93
Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis (2010) 0.93
Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Res Ther (2010) 0.91
Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum (2009) 0.89
Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract (2006) 0.89
Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford) (2012) 0.88
Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother (2013) 0.88
Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFα blockade: results from a prospective cohort study. Ann Rheum Dis (2010) 0.87
Bone metabolism is altered in preclinical rheumatoid arthritis. Ann Rheum Dis (2010) 0.87
Why do geriatric outpatients have so many moderate and severe vertebral fractures? Exploring prevalence and risk factors. Age Ageing (2012) 0.86
How to define responders in osteoarthritis. Curr Med Res Opin (2013) 0.86
Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. J Rheumatol (2004) 0.86
Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum (2007) 0.86
Niacin for reduction of cardiovascular risk. N Engl J Med (2014) 0.86
Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study. J Rheumatol (2010) 0.86
Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study. BMC Musculoskelet Disord (2013) 0.86
Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS). Calcif Tissue Int (2012) 0.85
Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep (2012) 0.85
Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis (2007) 0.85
Increased cardiovascular disease in patients with inflammatory arthritis in primary care: a cross-sectional observation. J Rheumatol (2009) 0.85
Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab. J Occup Environ Med (2010) 0.84
High disease activity is a predictor of cortical hand bone loss in post-menopausal patients with established rheumatoid arthritis: a 5-year multicentre longitudinal study. Rheumatology (Oxford) (2010) 0.84
Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome. Arthritis Res Ther (2009) 0.84
Osteoarthritis and osteoporosis: what is the overlap? Curr Rheumatol Rep (2013) 0.84
Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother (2015) 0.84
Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter (2007) 0.83
Predictors and outcome of pain-related avoidance of activities in persons with early symptomatic knee osteoarthritis: a five-year followup study. Arthritis Care Res (Hoboken) (2015) 0.83
Association of postural control with muscle strength, proprioception, self-reported knee instability and activity limitations in patients with knee osteoarthritis. J Rehabil Med (2013) 0.83
Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord (2011) 0.83
Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review. BMC Musculoskelet Disord (2014) 0.82
PTH analogues and osteoporotic fractures. Expert Opin Biol Ther (2010) 0.82
Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum (2006) 0.82
Clinical relevance of diagnosing vertebral fractures by vertebral fracture assessment. Curr Osteoporos Rep (2009) 0.82
The association of body-mass index and depressed mood with knee pain and activity limitations in knee osteoarthritis: results from the Amsterdam osteoarthritis cohort. BMC Musculoskelet Disord (2013) 0.82
Fracture risk estimation may facilitate the treatment gap in osteoporosis. Ann Rheum Dis (2015) 0.81
Serological bone markers and joint damage in early polyarthritis. J Rheumatol (2004) 0.81
High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. Clin Exp Rheumatol (2010) 0.81
Fracture prevention in COPD patients; a clinical 5-step approach. Respir Res (2015) 0.80
Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial. J Rheumatol (2003) 0.80
Osteoarthritis of the knee: multicompartmental or compartmental disease? Rheumatology (Oxford) (2013) 0.80
Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial. J Clin Gastroenterol (2009) 0.79
Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis. Ann Rheum Dis (2007) 0.79
Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial. Clin Rheumatol (2009) 0.79
Epidemiologic study of the autoimmune health effects of a cargo aircraft disaster. Arch Intern Med (2005) 0.78
Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. BMC Musculoskelet Disord (2009) 0.78
Development of fatal tuberculosis in a patient with rheumatoid arthritis after three years of treatment with infliximab: comment on the article by Wolfe et al. Arthritis Rheum (2005) 0.78
Biomechanical factors and physical examination findings in osteoarthritis of the knee: associations with tissue abnormalities assessed by conventional radiography and high-resolution 3.0 Tesla magnetic resonance imaging. Arthritis Res Ther (2012) 0.78
Association of serum C-reactive protein and erythrocyte sedimentation rate with muscle strength in patients with knee osteoarthritis. Rheumatology (Oxford) (2012) 0.78
Testing postural control among various osteoporotic patient groups: a literature review. Geriatr Gerontol Int (2012) 0.78
Early local swelling and tenderness are associated with large-joint damage after 8 years of treatment to target in patients with recent-onset rheumatoid arthritis. J Rheumatol (2013) 0.77
The avoidance model in knee and hip osteoarthritis: a systematic review of the evidence. J Behav Med (2014) 0.77
Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. J Cell Biochem (2012) 0.77
[Exercise therapy in hip or knee osteoarthritis]. Ned Tijdschr Geneeskd (2011) 0.77
Relevance of the new pre-cachexia and cachexia definitions for patients with rheumatoid arthritis. Clin Nutr (2012) 0.77
Elevated C-reactive protein is associated with lower increase in knee muscle strength in patients with knee osteoarthritis: a 2-year follow-up study in the Amsterdam Osteoarthritis (AMS-OA) cohort. Arthritis Res Ther (2014) 0.77
Knee joint stabilization therapy in patients with osteoarthritis of the knee and knee instability: subgroup analyses in a randomized, controlled trial. J Rehabil Med (2014) 0.77